Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
0.8723
-0.1227 (-12.33%)
At close: Jun 5, 2026, 4:00 PM EDT
0.8630
-0.0093 (-1.07%)
After-hours: Jun 5, 2026, 7:26 PM EDT
Celularity Employees
Celularity had 115 employees as of December 31, 2025. The number of employees decreased by 8 or -6.50% compared to the previous year.
Employees
115
Change (1Y)
-8
Growth (1Y)
-6.50%
Revenue / Employee
$230,870
Profits / Employee
-$798,261
Market Cap
25.25M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 115 | -8 | -6.50% |
| Dec 31, 2024 | 123 | 3 | 2.50% |
| Dec 31, 2023 | 120 | -105 | -46.67% |
| Dec 31, 2022 | 225 | 0 | - |
| Dec 31, 2021 | 225 | 63 | 38.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| IGC Pharma | 70 |
| Kyntra Bio | 34 |
| Lisata Therapeutics | 21 |
| NeuroSense Therapeutics | 17 |
| Quantum BioPharma | 17 |
| BriaCell Therapeutics | 16 |
| Serina Therapeutics | 16 |
| CervoMed | 15 |
CELU News
- 1 day ago - Celularity announces cenplacel-L availability for investigational use in Florida - TheFly
- 1 day ago - Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies - GlobeNewsWire
- 2 days ago - Celularity Releases CEO Letter to Shareholders - GlobeNewsWire
- 2 days ago - Celularity Appoints Rick Gonzalez as Chief Commercial Officer - GlobeNewsWire
- 7 days ago - Celularity Receives Nasdaq Notice Regarding Form 10-Q - GlobeNewsWire
- 5 weeks ago - Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - GlobeNewsWire
- 5 weeks ago - Celularity Annual report: Q4 2025 - Filings
- 5 weeks ago - NEXGEL Appoints Ian Blackman as Chief Financial Officer - GlobeNewsWire